title: Bevacizumab for the management of diabetic macular edema.
abstract: Diabetic retinopathy (DR) is a leading cause of vision loss in the working-age population and is relatedto 1%-5% of cases of blindness worldwide. Diabetic macular edema (DME) is the most frequent cause of DR vision loss and is an important public health problem. Recent studies have implicated vascular endothelial growth factor (VEGF) in DR and DME pathogenesis, as well as provided evidence of the benefits of anti-VEGF agents for the management of such conditions. Despite the benefits of intravitreal ranibizumab injection for the management of DME, the cost-effectiveness of intravitreal bevacizumab therapy has gained increasing interest in the scientific community. This review summarizes the studies examining bevacizumab for the management of DME, focusing on the efficacy and duration of the clinical benefits of decreasing DME and the improvement of best-corrected visual acuity (BCVA). There is strong evidence that intravitreal bevacizumab injection therapy has a good cost-effective profile in the management of DME and may be associated with laser photocoagulation; however, its clinical superiority in terms of the duration of DME regression and the improvement of BCVA compared with intravitreal ranibizumab and other intravitreal anti-VEGF therapies remains unclear and deserves further investigation.
authors.affiliation: Francisco Rosa Stefanini, Maurício Maia, The Retina Division, Ophthalmology Department, Federal University of São Paulo, São Paulo, SP 04023-062, Brazil.
authors.forename: Francisco Rosa
authors.initials: FR
authors.lastname: Stefanini
authors.forename: J Fernando
authors.initials: JF
authors.lastname: Arevalo
authors.forename: Maurício
authors.initials: M
authors.lastname: Maia
keywords: Anti-vascular endothelial growth factor; Bevacizumab; Diabetic macular edema; Diabetic retinopathy